Previous 10 | Next 10 |
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 29, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update before the U.S. markets open on Thu...
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell thera...
Thinly traded micro cap Adaptimmune Therapeutics plc ( ADAP +10.4% ) is up on modestly higher volume, albeit on turnover of only 306K shares, in reaction to the initiation of a 10-subject radiation sub-study evaluating its ADP-A2M4 SPEAR T cells in patients with solid tumors. More news...
- Compelling responses previously reported with ADP-A2M4 in sarcoma - - Use of low-dose radiation intended to enhance antitumor activity - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cel...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc, Philadelphia, PA, and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated SURPASS, its first clinical trial with a next-generation SPEAR T-cell ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This tran...
NetworkNewsWire Editorial Coverage : Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) ( GNPX Profile ) is leveraging its patented technology pla...
Adaptimmune ( ADAP +3.7% ) will collaborate with Alpine Immune Sciences ( ALPN +4.4% ) to develop next-generation SPEAR T-cell products based on the latter's secreted and transmembrane immunomodulatory protein (SIP and TIP) technology . More news on: Adaptimmune Therapeutics plc, Al...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatmen...
Thinly traded micro cap Adaptimmune Therapeutics (NASDAQ: ADAP ) is up 6% premarket on average volume in reaction to preliminary data in a pilot study of T-cell therapy candidate ADP-A2M4 . More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Read more ......
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...